Conclusion: Antibodies to cardiolipin were identified in 9% of patients undergoing infrainguinal vein bypass surgery and appeared to be associated with increased risk of bypass failure.
Introduction
Vein bypass is an established procedure in the management of lower extremity ischaemia providing longterm patency rates ranging from 60-90%. 14 Bypass failures occurring within i month have mainly been attributed to technical factors related to the operation. 4' 5 The majority of late failures occurring more than 2 years after surgery result from progressive atherosclerotic disease in the inflow artery, the graft, or the outflow artery. 4's Failures in the intermediate period between 1 month and 2 years after surgery constitute 70-80% of all failures and are mainly caused by graft or anastomotic stenoses. 4-9 Histopathological studies have shown that such peripheral vein bypass stenoses are characterised by intimal hyperplasia predominantly composed of smooth muscle cells and varying degrees of fibrosis. 8' 1°-12 Atherosclerotic changes are found only at a late stage. 8 The development of graft-related stenoses are assumed to be initiated by intraoperative vein injury inducing platelet aggregation and smooth muscle cell proliferation, leading to intimal thickening and subsequently to luminal narrowing. 5' 6' 13 The presence of morphological changes in the saphenous vein prior to bypass grafting have been found to increase the risk of postoperative development of stenoses. 14 ' 15 Serological risk factors predict the outcome after coronary artery bypass surgery, 16' 17 carotid endarterectomy 18' 19 or peripheral vascular interventions. 2~22 The primary aim of this study was to assess prospectively the association between antibodies to cardiolipin and patency of infrainguinal vein bypasses when conventional risk factors were allowed for. A secondary aim was to assess lipoprotein (a) and antibodies to oxidised low density lipoprotein (LDL) as predictors of vein bypass patency.
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Materials and Methods
Subjects
The study group comprised 103 patients scheduled for elective infrainguinal vein bypass surgery between July 1993 and May 1995. Another 190 patients who were operated on during the study period were not included for the following reasons: (i) anticoagulant treatment, (ii) vascular surgery or other interventional procedures within the last 3 months before surgery (which may all affect the levels of antibodies to cardiolipin), (iii) unwillingness to participate, (iv) emergency revascularisation (study personnel only present during daytime hours) or (v) participation in other research projects at our department (when more than one trial recruited patients, these were randomly assigned to either trial, to reduce the risk of selection bias). The study group did not differ from the remaining patients with respect to age, gender, smoking habits, diabetes, hypertension, indication for surgery or the level of the distal anastomosis. Twenty-three of the 103 patients were excluded at a later stage for the following reasons: seven were technically inoperable; in one patient dementia contraindicated surgery; eight patients in whom the saphenous vein was found to be inadequate had prosthetic grafts inserted (n = 7) or were referred to percutaneous transluminal angioplasty (n=l); and finally, preoperative blood samples were not available in seven patients. The median age of the remaining 53 men and 27 women was 70 (range 49-88). Ten (13%) patients had noninsulin dependent diabetes mellitus, and eight (10%) insulin-dependent diabetes mellitus. Previous aortoiliac (n=12) or infrainguinal (n=19) arterial reconstructions had been performed in 25 (31%) patients. At the time of surgery, 48 (60%) patients were current smokers and 16 (20%) had quit smoking within the previous 10 years. The indication for surgery was disabling claudication in 14 patients (18%), rest pain in 33 patients (41%) and ischaemic ulceration or gangrene in 33 patients (41%). Ulceration or gangrene occurred more often in patients with diabetes mellitus (78%) than in those without diabetes (31%) (p = 0.0009).
The study was approved by the local Research Ethics Committee and informed consent was obtained in all cases.
Surgery
Preoperative evaluation included diagnostic arteriography and ultrasound duplex imaging of the greater saphenous vein using an Interspec RX400 duplex scanner. Patent veins with an internal diameter of 2 mm or more were considered adequate. The level of the distal anastomosis was the above-knee popliteal artery in six patients (8%), the below-knee popliteal artery in 20 patients (25%) and a crural or pedal artery in 54 patients (68%). The bypass procedure was performed as described by Leather et aI. 1 For thrombosis prophylaxis, intravenous heparin (50 IU per kg body weight) was given during arterial clamping. After surgery the patients received subcutaneous low molecular weight heparin (Logiparin 3500IU daily) until mobilisation and, unless contraindicated, acetylsalicylic acid 500 mga day thereafter.
Bypass patency
Bypass surveillance consisted of ankle blood pressure measurements and ultrasound duplex scanning of the graft at 1 week, 6 weeks, 3, 6, 9 and 12 months. The ultrasound examinations were performed with either a B&K Medical 3535 or an ATL Ultramark 9 HDI duplex scanner. A localised increase in the peak systolic velocity of 250% or more in the graft was taken as indicating a significant stenosis. Rdintervention was considered in patients with abnormal duplex findings in combination with a reduction in the ankle-brachial index (ABI) of more than 0.15. In one patient, who at the initial duplex examinations had normal findings but during follow-up moved to another part of the country, bypass patency was assessed by her general practitioner.
Biochemical analysis
Plasma concentration of antibodies to cardiolipin, haemostatic factors, lipids and antibodies to oxidised LDL were measured 1-3 days prior to surgery and 6 weeks postoperatively. Measurements of these variables were only performed in the 80 patients included in the study and were assayed without knowledge of bypass patency. All preoperative blood samples were obtained after an overnight fast, but patients with diabetes were allowed breakfast prior to the postoperative sampling. Antibodies to cardiolipin were measured by an enzyme-linked immunosorbent assay as described by Mouritzen et al. 23 and is based on the procedure published by Loizou et al. 24 Patients with IgM antibody levels of >30 arbitrary units or IgG antibody levels of Eur J Vasc Endovasc Surg Vol 14, September 1997 >35 arbitrary units were considered antibody positive. Using these threshold values the frequency of serological positive tests in a normal control population is 1%. 23 Plasma cholesterol, triglycerides, cholesterol in high density lipoprotein (HDL) and LDL were determined enzymatically (CHOD-PAP and GPO-PAP, Boehringer Mannheim, Mannheim, Germany). Lipoprotein (a) was measured turbidimetrically (DAKO A/S, Glostrup, Denmark). Antibodies to oxidised LDL were detected as described by Vaarala et al. 25 using LDL modified by treatment with malondialdehyde as given by Palinski et al. 26 Fibrinogen was analysed by the IL Test TM PT-fibrinogen (Instrumentation Laboratory, Milano, Italy) according to the instructions of the manufacturer. Tissue plasminogen activator (t-PA) was measured by solid-phase immunosorbent assay 27 and plasminogen activator inhibitor 1 (PAI-1) was measured as previously described by Philips et al. 28 Continued smoking after surgery was assessed by determination of carboxyhaemoglobin at 6 weeks using an OSM3 Hemoximeter® (Radiometer, Copenhagen, Denmark) and a value of more than 2% was considered to indicate continued smoking.
Statistics
Continuous variables between the two groups were compared by the Mann-Whitney rank sum test. The Chi-squared test was used for comparison of categorical data. Primary 6 months' bypass patency without stenosis was calculated by the life-table method. Comparison of patency rates in the two groups was performed for serological risk factors and patient characteristics by the log rank test. For continuous variables the 50th as well as the 75th percentiles were initially tested as threshold values, and the threshold yielding the lowest p value was used in the final patency analysis. A Cox proportional hazard regression model was used to assess independent associations: variables with p values of 0.1 or less in the individual analyses were entered into the model. A confidence limit of less than 0.05 was considered statistically significant. All analysis were performed with the Statistica software programme.
Sample size calculation. Sample size was calculated as described by Altman. 29 It was assumed that antibodies to cardiolipin would be present in 20% of the patients and that the risk of bypass failure would be 70% in the antibody positive group as compared to 35% in the antibody negative group. On these assumptions 102 patients would be required to show a difference in bypass failure rate between the groups, with an 80% power and a significance level of 5%. The frequency of antibodies to cardiolipin and the relative risk were adopted from a study on patients undergoing coronary artery bypass surgery, 17 as no major trial assessing antibodies to cardiolipin in patients with infrainguinal vein bypasses was available when the study was initiated.
Results
Biochemical analysis
Preoperatively, antibodies to cardiolipin were present in seven (9%) patients; six males and one female with a median age of 70 (range 50-81). In five cases the antibodies were of the IgM isotype and in two cases of the IgG isotype. At 6 weeks no new patients had developed antibodies to cardiolipin.
Plasma levels of haemostatic factors, lipids and carboxyhaemoglobin preoperatively and at 6 weeks are presented in Table 1 . Values at 6 weeks postoperatively were not available for 18 patients who died or experienced early occlusion of the bypass. When serological risk factors were correlated with patient characteristics, it appeared that the preoperative fibrinogen level was higher in patients with ulceration or gangrene compared with those operated for claudication or rest pain (20 vs. 15 micromol/1, p = 0.002). 
Follow-up events
The median follow-up period for the entire study group was 6 months (range 0-12 months). All patients with patent bypasses were followed for at least 6 months. Among the 62 patients who stayed alive with patent bypasses at 30 days, graft-related stenoses were identified in 21 (34%): six stenoses were detected at 6 weeks, seven at 3 months, four at 6 months, two at 9 months and two at 12 months. Six surgical revisions of stenoses were performed in five patients. Ten bypasses thrombosed more than 30 days postoperatively. Five of these 10 late occlusions occurred in the group of 21 patients with diagnosed graft stenoses. The overall 6 months' primary bypass patency without stenosis was 53% (95% CI 42-65%).
Bypass patency according to risk factors
Among the seven patients who preoperatively had antibodies to cardiolipin, bypass thromboses occurred in four and graft stenoses were identified in another two ( Table 2) . Three of the four thromboses occurred within I month and one was detected at 3 months. Of the five patients who preoperatively had IgM isotype antibodies to cardiolipin, bypass thrombosis occurred in four. The fifth patient developed a bypass stenosis at 3 months, which had regressed at 12 months. Using the log rank test for univariate evaluation of individual risk factors, the presence of antibodies to cardiolipin and diabetes mellitus were both found to be correlated with graft patency without stenosis (Table 3) . On a Cox regression analysis in which variables with p values of 0.1 or less in the individual analysis were included, it was verified that diabetes mellitus and antibodies to cardiolipin each contributed independently in predicting the overall risk of bypass failure ( Table 4 ). The 95% CI of the relative risk for indication for surgery, fibrinogen and lipoprotein (a), however, all overlapped 1.0. Further stratification of patients according to time interval from surgery to the development of stenosis or thrombosis showed that no parameter predicted the risk of early (within 30 days after surgery) events. Among the 62 patients remaining at risk at 30 days, bypass patency free of stenosis was lower in patients with diabetes mellitus than in patients without (6 months' primary bypass patency 57% (95% C129-85%) vs. 68% (95% CI 55-81%), p = 0.05) and a preoperative plasma fibrinogen concentration above the 75th percentile was associated with reduced bypass patency (6 months' primary bypass patency free of stenosis 58% (95% CI 32-84%) vs. 67% (95% CI 54-81%), p = 0.05).
Discussion
Antibodies to cardiolipin as well as lupus anticoagulant were first described in patients with systemic lupus erythematosus (SLE). In recent years antibodies to cardiolipin have, however, also been Eur J Vasc Endovasc Surg Vol 14, September 1997 36 identified the presence of antibodies to cardiolipin as a major risk factor in cardiovascular surgery. During a 6-year period 19 patients with antibodies to cardiolipin underwent various cardiovascular surgical procedures. Sixteen (84%) anticardiolipin-positive patients suffered major postoperative complications related to either bleeding or thrombosis, and 12 (63%) died as a result of these complications. In a study on 83 patients undergoing coronary artery bypass grafting, Morton et al. 17 identified antibodies to cardiolipin as a risk factor for late graft occlusion, and these investigators suggested graft failure to be an autoimmune phenomenon. Likewise, Prieto et al. 37 found that antibodies to cardiolipin were associated with frequent thrombosis of haemodialysis fistulae. The present finding, that even low levels of antibodies to cardiolipin appeared to be associated with increased risk of infrainguinal bypass failure, has not previously been reported in a prospective followup study. Though the study was not based on a consecutive series of patients, we feel confident that the study group was representative of patients undergoing peripheral vein bypass surgery in our institution. Firstly, serological analyses were only performed in included patients, and therefore the antibody levels did not influence the recruitment, and secondly, patient characteristics were similar in the study group and the remaining patients operated on during the same period. Due to the rather small number of antibodypositive patients in this series, larger studies, preferably conducted as multicentre trials, are needed to confirm the role of antibodies to cardiolipin in the failure of infrainguinal vein bypasses.
The published prevalence of antibodies to cardiolipin in patients with peripheral vascular disease ranges from 8% to 24%. This variation may, at least partly, be explained by differences in methodology, as a number of tests for identification of antibodies to cardiolipin exist. Taylor et al. 3s found antibodies to cardiolipin in 55 of 234 patients admitted for peripheral vascular surgical procedures or amputation. Patients with antibodies to cardiolipin were 1.8 times more likely to have undergone previous lower extremity reconstruction and 5.6 times more likely to have experienced occlusion of a previous reconstruction. Fligelstone et aI. 39 assessed the incidence of antibodies to cardiolipin in 60 patients with peripheral aneurysmal or occlusive vascular disease and in 20 age-matched normal controls. Antibodies to cardiolipin were present in five (8%) patients as opposed to none in the control group. Similarly, antibodies were identified in seven (9%) patients preoperatively in this study. In the prospective study by Fligelstone et al. 39 and in this series, IgM was found to be the dominant isotype, but in the retrospective study by Taylor et al. s8 IgG was found more frequently.
The approximately 10% prevalence of antibodies to cardiolipin in patients undergoing peripheral vascular reconstruction, leading potentially to increased perioperative morbidity and mortality, suggests that in the future preoperative screening may be appropriate. However, before this is implemented further studies are needed to establish more firmly antibodies to cardiolipin as a risk factor for failure of infrainguinal vein bypasses. Treatment of the antiphospholipid syndrome is even more controversial. Steroids, cytostatics or gammaglobulin may be used to control disease activity, 3.'34 but in patients with no history of thrombotic events or other autoimmune symptoms the indication for systemic anti-inflammatory agents seems questionable. In patients with a clearcut antiphospholipid syndrome, closely controlled anticoagulant therapy is effective in preventing recurrent thrombosis. 4° The use of anticoagulants in patients with antibodies to cardiolipin who undergo peripheral vascular reconstruction should be considered, 4. though documentation is currently lacking.
In previous studies a raised plasma fibrinogen level has been found to be associated with a reduced patency of peripheral vein bypasses. 2°' 42 Though the influence of fibrinogen on overall bypass patency failed to achieve statistical significance in this study, the association between a raised fibrinogen concentration and an increased risk of late bypass failure supports the hypothesis of Hicks et al., 43 that fibrinogen is a risk factor for the development of graft stenoses. The finding of high fibrinogen levels in patients undergoing peripheral vascular surgery is in accord with previous observations. 39 The difference in plasma fibrinogen concentrations between patients with and without tissue loss presumably reflects the general increase of the acute phase proteins, which include fibrinogen, that occurs in response to critical ischaemia.
Smoking has been identified as an important risk factor for failure of vascular reconstructions in several publications. 19-21' 42 The lack of association between carboxyhaemoglobin at 6 weeks and bypass patency in this study may be related to the fact that a significant number of events occurred within 6 weeks. An immediate postoperative assay may be more valuable in studies with limited follow-up.
Hyperlipidaemia is causally related to the development of atherosclerosis, 44-46 but the role of lipids in the development of restenosis following vascular intervention is unclear. In retrospective studies, patients with restenosis following carotid endarterectomy were found to have higher levels of triglycerides and total cholesterol as compared to patients without evidence of restenosis. 18' 47 However, a recent prospective study on 107 patients indicated that hyperlipidaemia is a risk factor for restenosis after carotid endarterectomy only in women. 19 In a study by Wiseman et al., 2~ plasma lipids did not adversely influence patency of 93 prosthetic femoropopliteal grafts. Studying 167 patients who had had coronary artery bypass surgery 0.7-14.3 years earlier, Hoff et al. 16 found that serum lipoprotein (a) was twice as high in 135 patients with angiographic restenoses as in 32 patients without restenosis. Similarly, Cheshire et aI. 42 found a higher lipoprotein (a) level in patients with bypass stenoses than in patients with no evidence of stenoses in a mixed group of vein grafts and prosthetic bypasses. These authors did not address the influence of lipoprotein (a) on bypass patency. Confirming the findings of Wiseman et aI., 2° a raised plasma concentration of lipids was not a risk factor for bypass failure in this study.
Oxidation of LDL is probably involved in atherogenesis 48 and antibodies to oxidised LDL have been identified in a high proportion of patients with advanced atherosclerosis. 49 Our finding of a low incidence of antibodies to oxidised LDL in patients undergoing infrainguinal vein bypass surgery and the lack of association between these antibodies and bypass patency questions the role of LDL oxidation in the development of vein graft stenoses.
In conclusion, antibodies to cardiolipin were identified in 9% of patients undergoing infrainguinal vein bypass surgery and may be associated with increased risk of bypass failure.
